185 related articles for article (PubMed ID: 10129237)
1. MedWatch targets reporting of serious adverse events.
VanAmringe M
Jt Comm Perspect; 1993; 13(4):15. PubMed ID: 10129237
[No Abstract] [Full Text] [Related]
2. MedWatch. On lookout for medical product problems.
Ropp KL
FDA Consum; 1993 Nov; 27(9):14-7. PubMed ID: 10130376
[No Abstract] [Full Text] [Related]
3. Form for reporting serious adverse events and product problems with human drug and biological products and devices; availability--FDA. Notice.
Fed Regist; 1993 Jun; 58(105):31596-614. PubMed ID: 10171452
[TBL] [Abstract][Full Text] [Related]
4. MEDWatch: the new FDA medical products reporting program.
Kessler DA
Am J Hosp Pharm; 1993 Jun; 50(6):1151-2. PubMed ID: 8517452
[No Abstract] [Full Text] [Related]
5. MedWatch: the FDA medical products reporting program.
Rheinstein PH
Am Fam Physician; 1993 Sep; 48(4):636-8. PubMed ID: 8379493
[No Abstract] [Full Text] [Related]
6. MedWatch: the new medical products reporting program.
Couig MP; Merkatz RB
Am J Nurs; 1993 Aug; 93(8):65-8. PubMed ID: 8256839
[No Abstract] [Full Text] [Related]
7. MedWatch. FDA's 'heads up' on medical product safety.
Henkel J
FDA Consum; 1998; 32(6):10-2, 15. PubMed ID: 9854445
[No Abstract] [Full Text] [Related]
8. Reporting of adverse drug events: a key to postmarketing drug safety.
Rheinstein PH
Am Fam Physician; 1992 Sep; 46(3):873-4. PubMed ID: 1514478
[No Abstract] [Full Text] [Related]
9. Improving adverse drug reaction reporting in the community setting.
McCloskey BA
Med Interface; 1996 May; 9(5):85-7. PubMed ID: 10157690
[TBL] [Abstract][Full Text] [Related]
10. Strategy for surveillance of adverse drug events.
Bright RA
Food Drug Law J; 2007; 62(3):605-16. PubMed ID: 17915403
[No Abstract] [Full Text] [Related]
11. MEDWATCH: the new FDA medical products reporting program.
Kennedy DL
Respir Care; 1993 Oct; 38(10):1077-80. PubMed ID: 10145891
[No Abstract] [Full Text] [Related]
12. Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases.
Coté TR; Mohan AK; Polder JA; Walton MK; Braun MM
J Am Acad Dermatol; 2005 Sep; 53(3):407-15. PubMed ID: 16112345
[TBL] [Abstract][Full Text] [Related]
13. Serious adverse events in Norplant users related to the Food and Drug Administration's MedWatch Spontaneous Reporting System.
Chez RA
Obstet Gynecol; 1995 Jul; 86(1):154-5. PubMed ID: 7784014
[No Abstract] [Full Text] [Related]
14. Adverse drug reactions and reporting.
Witte R
Clin J Oncol Nurs; 2000; 4(4):181, 184. PubMed ID: 11261100
[No Abstract] [Full Text] [Related]
15. Vaccine adverse event reporting: the importance of follow-up.
Varricchio F
Expert Rev Vaccines; 2005 Aug; 4(4):445-8. PubMed ID: 16117700
[No Abstract] [Full Text] [Related]
16. Reporting adverse drug therapy results.
Pa Med; 1990 Jun; 93(6):29. PubMed ID: 2367135
[No Abstract] [Full Text] [Related]
17. Toward improved adverse event/suspected adverse drug reaction reporting.
Gross R; Strom BL
Pharmacoepidemiol Drug Saf; 2003 Mar; 12(2):89-91. PubMed ID: 12642971
[No Abstract] [Full Text] [Related]
18. Introducing MEDWatch. A new approach to reporting medication and device adverse effects and product problems.
Kessler DA
J Am Podiatr Med Assoc; 1994 Jan; 84(1):35-8. PubMed ID: 8295131
[No Abstract] [Full Text] [Related]
19. FDA guidance document on monitoring delayed adverse events a good first start.
Williams DA
Mol Ther; 2005 Dec; 12(6):991-2. PubMed ID: 16271514
[No Abstract] [Full Text] [Related]
20. Improving the quality of adverse drug reaction reporting by 4th-year medical students.
Rosebraugh CJ; Tsong Y; Zhou F; Chen M; Mackey AC; Flowers C; Toyer D; Flockhart DA; Honig PK
Pharmacoepidemiol Drug Saf; 2003 Mar; 12(2):97-101. PubMed ID: 12642973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
